Foresite Capital Management V LLC Invests $5.21 Million in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Foresite Capital Management V LLC acquired a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 8,133,047 shares of the company’s stock, valued at approximately $5,205,000. Lyell Immunopharma makes up approximately 4.3% of Foresite Capital Management V LLC’s holdings, making the stock its 6th largest position. Foresite Capital Management V LLC owned about 2.78% of Lyell Immunopharma as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. RPO LLC bought a new stake in shares of Lyell Immunopharma during the fourth quarter worth $42,000. Wells Fargo & Company MN increased its holdings in Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock worth $60,000 after purchasing an additional 20,542 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock valued at $75,000 after purchasing an additional 59,182 shares during the period. Barclays PLC lifted its holdings in shares of Lyell Immunopharma by 312.7% in the third quarter. Barclays PLC now owns 240,615 shares of the company’s stock valued at $332,000 after purchasing an additional 182,315 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in shares of Lyell Immunopharma during the fourth quarter worth about $162,000. 66.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

Lyell Immunopharma Trading Down 6.5 %

Shares of LYEL stock opened at $0.40 on Friday. The firm’s fifty day moving average price is $0.50 and its two-hundred day moving average price is $0.68. Lyell Immunopharma, Inc. has a 1 year low of $0.39 and a 1 year high of $2.88. The firm has a market capitalization of $118.14 million, a P/E ratio of -0.51 and a beta of -0.25.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, equities research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Insider Transactions at Lyell Immunopharma

In other news, Director Richard Klausner bought 158,000 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average cost of $0.60 per share, for a total transaction of $94,800.00. Following the completion of the acquisition, the director now owns 843,365 shares in the company, valued at approximately $506,019. This represents a 23.05 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sumant Ramachandra purchased 200,000 shares of the business’s stock in a transaction on Friday, March 21st. The stock was purchased at an average price of $0.58 per share, with a total value of $116,000.00. Following the purchase, the director now owns 200,000 shares of the company’s stock, valued at approximately $116,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 768,640 shares of company stock worth $449,508 in the last 90 days. Corporate insiders own 25.10% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.